Congress, drugmakers and doctors who specialize in areas outside cancer should listen when Oregon Health & Science University's Dr. Brian Druker and other oncologists say the FDA has a role to play in lowering drug prices by rewarding innovation sooner in the development process, according to this editorial. Curbing the high prices of patented medicines isn't only a matter of regulation and controls. It requires more effective and agile collaboration between drugmakers and research institutions, together with a more responsive FDA.

Related Summaries